Medicare AdvantageCoverageMedium impact
MA08.167, Pozelimab-bbfg (Veopoz®)
Independence Blue Cross·Oncology, Hematology, Rheumatology +1 more·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.167 for Pozelimab-bbfg (Veopoz®) has been reissued and will become effective May 28, 2025. This pharmacy policy update affects coverage and billing for this specialty medication.
Action Required
By May 28, 2025: Billing team should review the complete MA08.167 policy document at the source URL to understand specific coverage criteria and billing requirements for Pozelimab-bbfg (Veopoz®). Update prior authorization workflows and billing protocols as specified in the full policy.